Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 19, 2017
What is the competitive landscape for CUBIST PHARMS, and what generic alternatives to CUBIST PHARMS drugs are available?
CUBIST PHARMS has six approved drugs.| Patents: | 20 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 6 |
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;IV (INFUSION) | 021572-001 | Sep 12, 2003 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;IV (INFUSION) | 021572-001 | Sep 12, 2003 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
alvimopan | Capsules | 12 mg | ENTEREG | 6/16/2017 |
fidaxomicin | Tablets | 200 mg | DIFICID | 5/27/2015 |
daptomycin | For Injection | 500 mg/vial | CUBICIN | 11/19/2008 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9,624,250 | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate | ► Subscribe | |||||||||||||||||||||||||||
| 7,696,220 | Methods for the treatment or inhibition of ileus | ► Subscribe | |||||||||||||||||||||||||||
| 8,883,986 | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | ► Subscribe | |||||||||||||||||||||||||||
| 8,728,796 | Tiacumicin production | ► Subscribe | |||||||||||||||||||||||||||
| 9,662,397 | Lipopeptide compositions and related methods | ► Subscribe | |||||||||||||||||||||||||||
| 8,518,899 | Macrocyclic polymorphs, compositions comprising such polymorphs and methods of use and manufacture thereof | ► Subscribe | |||||||||||||||||||||||||||
| 9,044,485 | Ceftolozane antibiotic compositions | ► Subscribe | |||||||||||||||||||||||||||
| 8,835,382 | Lipopeptide compositions and related methods | ► Subscribe | |||||||||||||||||||||||||||
| 7,507,564 | Tiacumicin production | ► Subscribe | |||||||||||||||||||||||||||
| 9,163,043 | Oxazolidinone derivatives | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia | 2016200570 | ► Subscribe | |||||||||||||||||||||||||||
| Portugal | 1699784 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 2777705 | ► Subscribe | |||||||||||||||||||||||||||
| Taiwan | 200840562 | ► Subscribe | |||||||||||||||||||||||||||
| China | 1708502 | ► Subscribe | |||||||||||||||||||||||||||
| China | 1894242 | ► Subscribe | |||||||||||||||||||||||||||
| Luxembourg | 92834 | ► Subscribe | |||||||||||||||||||||||||||
| Singapore | 10201407724Y | ► Subscribe | |||||||||||||||||||||||||||
| World Intellectual Property Organization (WIPO) | 2015048217 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 1940417 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0028 | France | ► Subscribe | PRODUCT NAME: FIDAXOMICINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111207 | ||||||||||||||||||||||||||
| 0759 | Netherlands | ► Subscribe | PRODUCT NAME: TEDIZOLID, DESGEWENST IN DE VORM VAN EEN ESTER, IN HET BIJZONDER EEN FOSFAAT, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/15/991 20150323 | ||||||||||||||||||||||||||
| C0022 | France | ► Subscribe | PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119 | ||||||||||||||||||||||||||
| 3 50021-2015 | Slovakia | ► Subscribe | PRODUCT NAME: TEDIZOLIDFOSFAT; REGISTRATION NO/DATE: EU/1/15/991/001 - EU/1/15/991/003 20150325 | ||||||||||||||||||||||||||
| 0727 | Netherlands | ► Subscribe | PRODUCT NAME: FIDAXOMICINE; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111207 | ||||||||||||||||||||||||||
| 943 | Luxembourg | ► Subscribe | PRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922 | ||||||||||||||||||||||||||
| C0062 | France | ► Subscribe | PRODUCT NAME: TEDIZOLIDE,EVENTUELLEMENT SOUS LA FORME D'UN ESTER ,EN PARTICULIER UN PHOSPHATE,OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/991 20150325 | ||||||||||||||||||||||||||
| 2015000078 | Germany | ► Subscribe | PRODUCT NAME: TEDIZOLID, GEGEBENENFALLS IN FORM EINES ESTERS, INSBESONDERE EINES PHOSPHATS, ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/991/001-003 20150323 | ||||||||||||||||||||||||||
| 2016 00004 | Denmark | ► Subscribe | PRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922 | ||||||||||||||||||||||||||
| 0762 | Netherlands | ► Subscribe | PRODUCT NAME: TEDIZOLID, DESGEWENST IN DE VORM VAN EEN ESTER, IN HET BIJZONDER EEN FOSFAAT, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/15/991 20150323 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,662 others who get our Drug Patent Expiration Alerts:
